share_log

Baird Maintains Neutral on Amylyx Pharma, Lowers Price Target to $3

Moomoo 24/7 ·  Apr 11 06:43

Baird analyst Joel Beatty maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and lowers the price target from $4 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment